Page 6 - ANWITA DEVELOPMENT TO TT

R&D EXPERTISE

Avg. No. of
Designation Qualification Market Expertise Dosage Forms Handled Therapeutic Areas
Experience Personnel
Technical Team
Team Leaders 1 ❖ Tablets/Capsules
Formulation Ph. D / Masters in ❖ Immediate Release
15-20 Years ❖ US ❖ Extended release ❖ Anti-Neoplastic (Oncology):
Team Leaders 1 Pharmacy. ❖ Europe ❖ Controlled and Delayed release ❖ Abiraterone, Erlotinib
Analytical ❖ Canada ❖ Oral liquids ❖ Anti-Hypertensive (Cardiovascular):
❖ LATAM ❖ Solutions ❖ Atenolol/ Nifedipine ER Tablet in Capsule
❖ ASEAN ❖ Immunomodulators (Multiple Sclerosis):
Senior Scientist 2 ❖ Australia/New Zealand ❖ Suspensions ❖ Fingolimod, Teriflunomide, Dimethyl
Formulation ❖ GCC ❖ Liposomes Fumarate DR
Master of Science / ❖ Russia/CIS ❖ Dermal / transdermal ❖ Anti-Coagulants:
7-10 Years ❖ Emulsions
Masters in Pharmacy ❖ MENA ❖ Dabigatran
Senior Scientist ❖ WHO-PEPFAR ❖ Depotherapy ❖ Metabolic Disorder (Diabetes):
Analytical 2 ❖ Ophthalmic ❖ Metformin ER, Sitagliptin/Metformin
❖ Injectables ❖ Gastric Acid Secretion Inhibitor:
❖ Esomeprazole MUPS Tablets
Junior Scientist 6 ❖ Anti-retroviral:
Formulation ❖ Darunavir, Tenofovir
❖ Antidepressants (CNS):
Masters in Pharmacy / ❖ US ❖ Duloxetine DR, Fluoxetine DR
Masters in Science / ❖ Immediate and Extended release ❖ Anti-inflammatory/allergy:
1-5 Years Bachelors in Pharmacy ❖ EU oral dosage forms
Senior Scientist 18 ❖ Rest of World ❖ Ebastin ODT,
Analytical / Bachelors in Science Fexofenadine/Pseudoephedrine ER,
Zileuton ER